bioSyntagma
Eliminating trial-and-error cancer treatments through biomarker discovery and predictive analytics
Eliminating trial-and-error cancer treatments through biomarker discovery and predictive analytics
bioSyntagma is a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. The company’s Molecular Fingerprint™ (mPrint™) platform creates a comprehensive, multi-omic and spatial profile of tissue to get a complete and informed understanding of the patient’s cancer so they can be matched with relevant therapies and recommended course of actions that prevent acquired drug resistance. bioSyntagma’s mPrint™ platform serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $196.00K | 1 | National Institutes of Health | 19 Mar 2018 |
| Grant | $892.09K | 1 |
|
06 Feb 2018 |
| Grant | $214.00K | 1 |
|
01 Jan 2017 |
| Grant | $80.00K | - | 05 Oct 2016 |
No recent news or press coverage available for bioSyntagma.
We care about your data, and we'd love to use cookies make your experience better.
